Alkem Labs shares in focus as Goldman, Morgan Stanley, others purchase stake in Rs 930-crore block deal
Alkem Laboratories' shares were in focus following a ₹930 crore block deal where institutional investors, including Goldman Sachs and Morgan Stanley, purchased a 2.6% equity stake. The transaction involved existing entities selling their shares.
Jun 03 2026 08:59:47
Alkem Labs sees Rs 930 crore block deal as promoter family entities pare stake; Goldman, Morgan Stanley among key buyers
Alkem Laboratories' promoters divested a 1.5% stake in the company for ₹930 crore through open market transactions. The sale involved approximately 17.88 lakh shares at an average price of ₹5,200 per share.
Jun 02 2026 21:32:13
Alkem Laboratories Ltd - 539523 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Alkem Laboratories has become the first Indian company to launch semaglutide in single-shot pre-filled syringes for Type 2 diabetes and obesity. This affordable new format, priced from INR350, aims to improve patient access and convenience.
Jun 02 2026 15:17:29
Block deal launched in Alkem Laboratories, up to 1.5% stake on offer
A block deal has been launched in Alkem Laboratories, offering up to 1.5% equity stake at a floor price of ₹4,800 per share. This price represents a 6.7% discount from the stock's previous day's closing price, indicating potential selling pressure on the shares.
Jun 01 2026 19:26:47
Alkem Laboratories Limited
Alkem Laboratories has released the transcript of its Q4 and FY26 earnings call, which took place on May 28, 2026. This transcript, uploaded to the company's website on June 1, 2026, offers detailed insights into the company's performance and strategy.
Jun 01 2026 17:52:33
Alkem Laboratories Limited
Alkem Laboratories discussed its Q4 and full FY26 results in an earnings call, highlighting a landmark year with record EBITDA and strong broad-based growth. The company expects to continue outperforming the market by 100-150 basis points in FY27, driven by new product launches.
Jun 01 2026 16:37:14
Alkem Laboratories Limited
Alkem Laboratories declared a final dividend of Rs. 10 per equity share for the financial year ended March 31, 2026. The record date for the dividend is August 7, 2026, and payment will be made by September 1, 2026.
May 28 2026 16:03:52
Alkem Laboratories Ltd - 539523 - Corporate Action - Fixes Record Date For Payment Of Dividend And Cut Off For AGM
Alkem Laboratories set August 7, 2026, as the record date for its final dividend of ₹2 per equity share for FY26. The dividend is payable from September 1, 2026, subject to shareholder approval.
May 28 2026 13:37:33
Alkem Laboratories Ltd - 539523 - Corporate Action-Board approves Dividend
Alkem Laboratories board recommended a final dividend of ₹10 per equity share for FY26. The dividend payment is scheduled to commence on September 1, 2026, following shareholder approval.
May 28 2026 13:34:51
Alkem Laboratories Ltd - 539523 - Announcement under Regulation 30 (LODR)-Change in Directorate
Alkem Laboratories' Board re-appointed Mrs. Madhurima Singh as an Executive Director for 5 consecutive years. Her new term will commence on December 20, 2026, and is subject to shareholder approval at the upcoming Annual General Meeting. This ensures continuity in key leadership.
May 28 2026 13:32:22
Read More